证券代码：688358 证券简称：祥生医疗 公告编号：2025-029 （一） 股东大会召开的时间：2025 年 9 月 16 日 （二） 股东大会召开的地点：无锡市新吴区新辉环路 9 号 公司一楼会议室 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 无锡祥生医疗科技股份有限公司 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 36 | | --- | --- | | 普通股股东人数 | 36 | | 2、出席会议的股东所持有的表决权数量 | 82,326,945 | | 普通股股东所持有表决权数量 | 82,326,945 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 73.5885 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 73.5885 | （四） 表 ...

Group 1 - The core viewpoint of the article is that Pacific Securities has issued a buy rating for Xiangsheng Medical (688358.SH) based on several positive factors [1] - The implementation of SonoAI is expected to reshape the diagnostic and treatment chain [1] - The company is increasing its investment in scanning robots to enhance breast cancer screening efforts [1] - The gross profit margin remains stable, although there is a slight increase in expenses [1] Group 2 - There are risks associated with a slowdown in bidding processes, risks from centralized procurement of equipment, and the potential for new business development to underperform expectations [1]

Core Viewpoint - Xiangsheng Medical (688358) has shown a positive stock performance with a 4.61% increase, reflecting strong market interest and ongoing innovation in the ultrasound medical device sector [1]. Group 1: Financial Performance - As of September 12, 2025, Xiangsheng Medical's stock closed at 31.12 yuan, up from 29.75 yuan the previous week, with a market capitalization of 3.483 billion yuan [1]. - The company reported a research and development investment of 37.6131 million yuan in the first half of 2025, which constitutes 15.93% of its revenue [3]. Group 2: Product Development and Innovation - The entire range of digital color ultrasound diagnostic products received certification under the EU Medical Devices Regulation (MDR) in July 2025, positioning the company among the few in China with a complete product line certified in one upgrade [1]. - The "Breast Artificial Intelligence Ultrasound Robot" has obtained a medical device testing report, integrating ultrasound, robotics, and AI for automated management of breast health screening and treatment [1]. - The SonoVet series of veterinary ultrasound products has been launched, addressing the needs of large animal reproduction and small animal abdominal and cardiovascular examinations, and has entered the global pet ultrasound market [2][3].

近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-09-11 | 30.91 | 1.48% | 473.19万 | 13.15% | -277.70万 | -7.72% | -195.49万 | -5.43% | | 2025-09-10 | 30.46 | 1.30% | e 75.77万 | 2.14% | -72.33万 | -2.04% | -3.45万 | -0.10% | | 2025-09-09 | 30.07 | -3.00% | 204.38万 | 4.12% | 428.72万 | 8.63% | -633.10万 | -12.75% | | 2025-09-08 | 31.00 | 4.20% | 127.31万 | 1.82% | 9.92万 | 0.14% | -137.24万 | -1.96% | | 2025-09-05 | 29.75 | 1.74% | ...

Group 1 - The core point of the news is that the main funds in the Shanghai and Shenzhen markets saw a net inflow of 34.518 billion yuan, with the Sci-Tech Innovation Board experiencing a net inflow of 2.309 billion yuan [1] - A total of 230 stocks on the Sci-Tech Innovation Board saw net inflows, while 358 stocks experienced net outflows [1] - Among the stocks with significant net inflows, Haiguang Information led with a net inflow of 2.467 billion yuan, followed by Shijia Photon and Dingtong Technology with net inflows of 369 million yuan and 234 million yuan respectively [1] Group 2 - There are 37 stocks that have seen continuous net inflows for more than three trading days, with Hanwujing leading at 17 consecutive days of inflow [2] - Conversely, 150 stocks have experienced continuous net outflows, with Xianfeng Precision leading at 14 consecutive days of outflow [2] - The top three stocks by net inflow include Haiguang Information, Shijia Photon, and Dingtong Technology, with inflows of 246.719 million yuan, 36.891 million yuan, and 23.406 million yuan respectively [2] Group 3 - The overall market performance shows that 524 stocks on the Sci-Tech Innovation Board rose, with six stocks hitting the daily limit up, including Juguang Technology and Tengjing Technology [1] - The stock with the largest net outflow was BeiGene, which saw a net outflow of 229 million yuan and a decline of 3.73% [1] - Other notable stocks with significant net outflows include Jiayuan Technology and Tianyue Advanced, with outflows of 215 million yuan and 147 million yuan respectively [1]

Core Viewpoint - Xiangsheng Medical's stock has shown volatility with a year-to-date increase of 29.71%, but a recent decline of 12.45% over the past 20 days indicates potential concerns in market performance [1][2]. Financial Performance - For the first half of 2025, Xiangsheng Medical reported revenue of 236 million yuan, a year-on-year decrease of 4.61%, and a net profit attributable to shareholders of 69.7 million yuan, down 14.32% compared to the previous year [2]. - Cumulative cash dividends since the company's A-share listing amount to 464 million yuan, with 280 million yuan distributed over the last three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 1.87% to 6,631, while the average number of circulating shares per person decreased by 1.84% to 16,909 shares [2]. - Among the top ten circulating shareholders, notable changes include a stable holding of 603,300 shares by Changcheng Consumption Value Mixed A, while Huazhong Hongli Mixed A reduced its holdings by 567,400 shares [3]. Market Activity - On September 9, 2023, Xiangsheng Medical's stock price was 30.38 yuan per share, with a trading volume of 26.21 million yuan and a turnover rate of 0.76% [1]. - The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent occurrence on February 17 [1].

Core Viewpoint - Xiangsheng Medical (688358) is focusing on innovation and development in the ultrasound field, with significant investments in R&D and a commitment to expanding its product offerings and market presence [2][6]. R&D Investment - In the first half of 2025, the company invested 37.61 million RMB in R&D, accounting for 15.93% of its revenue [2]. - The company has received 43 foreign market access licenses this year, enhancing its overseas market share [2]. Product Development - The company has developed the "AI + Ultrasound Robot" product, which integrates visual recognition and robotic control technologies to address mass screening challenges for malignant tumors [3]. - The "Breast AI Ultrasound Robot" has received medical device testing reports, targeting breast cancer, and aims to establish a comprehensive breast health management model in China [3]. Technological Ecosystem - The company has established a collaborative system in the "I + Robot" field, integrating technology for enhanced diagnostic precision and operational efficiency [4]. Veterinary Ultrasound Products - The company has launched the SonoVet series for veterinary ultrasound, addressing traditional challenges in image resolution and operational dependency on experience [5]. Financial Performance - For the first half of 2025, the company reported a main revenue of 236 million RMB, a year-on-year decrease of 4.61%, and a net profit of approximately 69.70 million RMB, down 14.32% [6]. - The second quarter of 2025 saw a main revenue of 108 million RMB, a slight increase of 1.37% year-on-year, but a net profit decline of 21.57% [6]. Market Outlook - Analysts have provided profit forecasts for the company, with expected net profits of 165 million RMB in 2025, 192 million RMB in 2026, and 222 million RMB in 2027 [6].

Group 1 - The stock price of Chison Medical (688358) closed at 29.75 yuan on September 5, 2025, with an increase of 1.74% and a turnover rate of 1.27% [1] - On September 5, 2025, the net inflow of main funds was 242.03 thousand yuan, while retail investors experienced a net outflow of 307.67 thousand yuan [3] - Chison Medical will participate in the 2025 semi-annual performance briefing for the medical device industry on September 17, 2025, where the company will discuss its operating results and financial status with investors [1][3] Group 2 - Chison Medical plans to hold its first extraordinary general meeting of shareholders in 2025 on September 16, 2025, to discuss the cancellation of the supervisory board and amendments to the company's articles of association [2] - The supervisory board's functions will be transferred to the audit committee of the board of directors, and relevant amendments to the company's governance documents will be proposed [2]

Core Viewpoint - The company, Xiangsheng Medical, has experienced a decline in revenue and net profit in the first half of 2025, while continuing to invest in research and development for innovative ultrasound technologies [1][4]. Financial Performance - For the first half of 2025, the company reported revenue of 236.15 million yuan, a year-on-year decrease of 4.61% - The net profit attributable to shareholders was 69.70 million yuan, down 14.32% year-on-year - The net profit after deducting non-recurring items was 63.83 million yuan, a decline of 14.10% year-on-year [1][4]. Research and Development - The company invested 37.61 million yuan in research and development, accounting for 15.93% of its revenue - The workforce includes 178 R&D personnel, representing 34.30% of the total staff - Ongoing projects include the development of "I+ cardiac ultrasound," "I+ obstetric ultrasound," "I+ animal ultrasound," and "I+ ultrasound scanning robots" [1][4]. Product Development - The company launched the "I+ Robot Scanning" series, integrating visual recognition, precise robotic control, and AI-assisted screening systems - The breast artificial intelligence ultrasound robot has received a medical device testing report, featuring a touchscreen, electric examination bed, six-degree-of-freedom robotic arm, automatic image transmission, and AI-assisted reading capabilities - A partnership with the Gates Foundation was established in July 2025 to jointly develop intelligent obstetric and breast ultrasound screening equipment [2]. Corporate Announcements - Xiangsheng Medical will participate in a collective performance briefing for the medical device industry on September 17, 2025, with key personnel attending [3]. - The company plans to hold its first extraordinary general meeting of 2025 to discuss the cancellation of the supervisory board and amendments to the Articles of Association, with voting conducted both on-site and online [3][4].

Core Points - The company is holding its first extraordinary general meeting of shareholders in 2025 to ensure the rights of all shareholders and maintain order during the meeting [1][2] - The meeting will discuss the cancellation of the supervisory board and amendments to the company's articles of association, with the supervisory board's functions being transferred to the audit committee of the board of directors [6][7] - The company will also revise, abolish, and establish certain internal governance systems to enhance its governance structure [8][10] Meeting Procedures - The meeting will include a sign-in process for attendees, followed by the announcement of the number of shareholders present and their voting rights [6] - Shareholders and their representatives will have the right to speak, inquire, and vote during the meeting, with specific procedures for raising questions and making statements [2][3] - Voting will be conducted through a combination of on-site and online methods, with specific time frames for each [5][6] Agenda Items - The first agenda item is the proposal to cancel the supervisory board and amend the articles of association, which has already been approved by the board of directors and the supervisory board [7][8] - The second agenda item involves the revision and establishment of certain internal governance systems, which also requires shareholder approval [8][10]